
Opinion|Videos|May 5, 2025
Lorlatinib in Focus: Survival, Brain Metastases, and Beyond
Panelists discuss how the 5-year CROWN trial data for lorlatinib have shaped the treatment paradigm for ALK+ metastatic non-small cell lung cancer (NSCLC), particularly regarding long-term survival, durability of response, and management of brain metastases.
Advertisement
Episodes in this series

Panel Introduction
CROWN Trial and Lorlatinib Treatment in ALK+ Metastatic NSCLC
- Discussion focused on the 5-year data from the CROWN trial evaluating lorlatinib for ALK-positive metastatic NSCLC
- Analysis of how these long-term outcomes have influenced the current treatment paradigm
- Comparison of clinical trial results with real-world outcomes observed by treating physicians
Key Treatment Considerations
- Long-term survival benefits and durability of response with lorlatinib
- Emphasis on efficacy against brain metastases, which are common in ALK+ NSCLC
- Cost-effectiveness evaluations when selecting frontline treatment options
Clinical Implementation
- Real-world efficacy and safety profile of lorlatinib compared to clinical trial results
- Practical considerations in implementing treatments based on CROWN trial evidence
- Balance between efficacy outcomes and economic considerations in treatment decisions
Notable Insights
- Dr. Dietrich was asked to describe the CROWN trial design and elaborate on how the 5-year data has influenced the treatment landscape for ALK+ metastatic NSCLC, particularly regarding survival outcomes and response durability.
- Dr. Lovly addressed the unique long-term outcomes with lorlatinib, especially its efficacy against brain metastases, and discussed the complex balance between cost considerations and clinical efficacy when making frontline treatment decisions.
- Castronovo provided perspective on real-world clinical experience with lorlatinib, comparing observed efficacy and safety profiles with those reported in the controlled CROWN trial setting.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis
2
Amgen Direct-to-Patient Program Aims to Expand Access to Evolocumab Amid US Drug Pricing Reforms
3
Cohere Health Findings on AI in Prior Authorization Conflict With AMA Data
4
Contributor: Why Public Health Keeps Failing—and How to Fix It
5